Zacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of “Strong Buy” from Brokerages

Checkpoint Therapeutics Inc (NASDAQ:CKPT) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus target price of $15.50 for the company and are forecasting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also given Checkpoint Therapeutics an industry rank of 156 out of 255 based on the ratings given to its competitors.

A number of equities analysts recently commented on CKPT shares. Zacks Investment Research upgraded Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price objective on the stock in a report on Wednesday, March 21st. ValuEngine upgraded Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Checkpoint Therapeutics in a report on Friday, May 11th.

Checkpoint Therapeutics traded down $0.05, reaching $3.02, during mid-day trading on Monday, reports. The stock had a trading volume of 8,212 shares, compared to its average volume of 64,242. Checkpoint Therapeutics has a fifty-two week low of $2.97 and a fifty-two week high of $10.50. The company has a market capitalization of $104.69 million and a P/E ratio of -3.02.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.13). Checkpoint Therapeutics had a negative return on equity of 122.20% and a negative net margin of 1,967.93%. The firm had revenue of $0.34 million during the quarter. equities analysts predict that Checkpoint Therapeutics will post -1.36 earnings per share for the current year.

A hedge fund recently bought a new stake in Checkpoint Therapeutics stock. Millennium Management LLC bought a new position in shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 75,390 shares of the company’s stock, valued at approximately $331,000. Millennium Management LLC owned 0.24% of Checkpoint Therapeutics as of its most recent SEC filing. 1.47% of the stock is currently owned by institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply